Transgelin Contributes to a Poor Response of Metastatic Renal Cell Carcinoma to Sunitinib Treatment

Renal cell carcinoma (RCC) represents about 2–3% of all cancers with over 400,000 new cases per year. Sunitinib, a vascular endothelial growth factor tyrosine kinase receptor inhibitor, has been used mainly for first-line treatment of metastatic clear-cell RCC with good or intermediate prognosis. Ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Bouchalova, Pavla, Beranek, Jindrich, Lapcik, Petr, Potesil, David, Podhorec, Jan, Poprach, Alexandr, Bouchal, Pavel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467952/
https://www.ncbi.nlm.nih.gov/pubmed/34572331
http://dx.doi.org/10.3390/biomedicines9091145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467952/
https://www.ncbi.nlm.nih.gov/pubmed/34572331
http://dx.doi.org/10.3390/biomedicines9091145

Ejemplares similares